Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
CeriBell, Inc. is a medical technology company operating in the neurodiagnostics and medical devices industries, with a primary focus on improving the diagnosis and management of neurological conditions. The company is best known for its portable, point-of-care electroencephalography (EEG) solutions designed to rapidly detect and monitor brain activity, particularly in acute care settings. Its core offering addresses critical unmet needs in identifying non-convulsive seizures and status epilepticus, conditions that are often underdiagnosed due to the limitations of traditional EEG systems.
Founded in 2014, CeriBell evolved from an early-stage neurotechnology startup into a commercial-stage medical device company. Its growth has been driven by increasing adoption of rapid EEG technology in hospitals, regulatory clearances for its flagship systems, and expanding clinical evidence supporting its use in emergency departments and intensive care units. The company completed an initial public offering in 2024 and is listed on the Nasdaq Global Market under the ticker CBLL.
Business Operations
CeriBell generates revenue primarily through the sale and use of its proprietary Rapid Response EEG™ System, which includes a disposable headband, portable EEG recorder, and cloud-based software for real-time brain monitoring. The system is designed for ease of use by non-specialist clinicians, enabling faster diagnostic decision-making compared to conventional EEG setups that require trained technologists and neurologists.
Operations are primarily commercialized in the United States, with international sales conducted through distributors in select markets. The company controls its core hardware design, software algorithms, and cloud-based analytics platform, while leveraging contract manufacturing for production. CeriBell also provides recurring revenue through disposable components and software-related services associated with ongoing clinical use.
Strategic Position & Investments
CeriBell’s strategy centers on expanding the clinical adoption of rapid EEG as a standard of care in emergency and critical care environments. Growth initiatives include increasing hospital penetration, broadening clinical indications, and strengthening reimbursement pathways. The company continues to invest in clinical studies and real-world evidence to support expanded use cases and guideline inclusion.
The company has not disclosed large-scale acquisitions as of the most recent public filings, instead prioritizing internal research and development. Strategic investments focus on enhancing signal processing, automation, and artificial intelligence–driven analytics within its EEG platform. These efforts position CeriBell at the intersection of digital health, neurology, and acute care diagnostics, with an emphasis on scalable, software-enabled medical devices.
Geographic Footprint
CeriBell is headquartered in Sunnyvale, California, within the United States, and its primary commercial operations are concentrated in North America. The U.S. represents the majority of revenue, driven by hospital systems, emergency departments, and intensive care units adopting rapid EEG technology.
Internationally, the company maintains a growing presence across Europe, Asia-Pacific, and select other regions through distribution partners. While international revenue remains a smaller portion of total sales, these markets represent long-term growth opportunities as awareness of rapid EEG and acute neurological diagnostics increases globally.
Leadership & Governance
CeriBell is led by an experienced management team with backgrounds in medical devices, healthcare commercialization, and technology innovation. The leadership emphasizes clinical impact, evidence-based adoption, and disciplined growth as core elements of its strategic vision.
Key executives include:
- Xavier McGorty – President and Chief Executive Officer
- Charit Bhogaraju – Chief Financial Officer
- Peter Manzoni – Chief Operating Officer
- Dr. David R. Gibbs – Chief Medical Officer
- Paul Sher – Chief Commercial Officer
The company operates under a board-governed structure consistent with U.S. public company standards, with oversight informed by regulatory compliance, clinical quality, and long-term shareholder value creation.